|
Market Closed -
Other stock markets
|
Pre-market 09:07:40 am | |||
| 95.47 USD | -6.00% |
|
95.85 | +0.40% |
Business description: Abbott Laboratories
- vascular devices (48.3%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
- diagnostic systems and instruments (20.2%);
- nutrition products (19.1%): pediatric nutrition products, nutritional supplements, and dietetic products;
- medicine (12.4%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.
Net sales are distributed geographically as follows: the United States (38.7%), Germany (6.2%), China (4.3%), India (4.2%), Switzerland (4.2%), Japan (3.3%), the United Kingdom (3%) and others (36.1%).
Number of employees: 115,000
Sales by Activity: Abbott Laboratories
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Medical Devices | 14.37B | 14.69B | 16.89B | 18.99B | 21.39B |
Diagnostics | 15.64B | 16.58B | 9.99B | 9.34B | 8.94B |
Nutrition | 8.29B | 7.46B | 8.15B | 8.41B | 8.45B |
Established Pharmaceutical | 4.72B | 4.91B | 5.07B | 5.19B | 5.54B |
Other | 52M | 11M | 14M | 16M | 17M |
Geographical breakdown of sales: Abbott Laboratories
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 16.64B | 18.14B | 15.45B | 16.32B | 17.13B |
All Other Countries | 15.52B | 14.84B | 14.08B | 14.85B | 15.98B |
Germany | 2.57B | 2.34B | 2.34B | 2.54B | 2.76B |
China | 2.39B | 2.13B | 2.25B | 2.11B | 1.91B |
Switzerland | 1.31B | 1.34B | 1.64B | 1.75B | 1.87B |
India | 1.56B | 1.65B | 1.75B | 1.82B | 1.87B |
Japan | 1.7B | 1.93B | 1.51B | 1.44B | 1.48B |
United Kingdom | - | - | - | - | 1.34B |
The Netherlands | - | - | 1.07B | 1.12B | - |
Canada | 1.38B | 1.28B | - | - | - |
Executive Committee: Abbott Laboratories
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 52 | 2020-03-30 |
Philip Boudreau
DFI | Director of Finance/CFO | 53 | 2023-08-31 |
Sabina Ewing
CIO | Chief Investment Officer | 51 | - |
Scott House
CTO | Chief Tech/Sci/R&D Officer | - | 2020-02-29 |
Melissa Brotz
SAM | Sales & Marketing | - | - |
Composition of the Board of Directors: Abbott Laboratories
| Director | Title | Age | Since |
|---|---|---|---|
Robert Alpern
BRD | Director/Board Member | 75 | 2008-10-09 |
Sally Blount
BRD | Director/Board Member | 64 | 2011-12-08 |
Nancy McKinstry
BRD | Director/Board Member | 67 | 2011-12-08 |
Daniel Starks
BRD | Director/Board Member | 71 | 2017-02-15 |
John Stratton
BRD | Director/Board Member | 65 | 2017-06-28 |
Robert Ford
CHM | Chairman | 52 | 2021-12-09 |
Michelle Kumbier
BRD | Director/Board Member | 58 | 2018-06-07 |
Darren McDew
BRD | Director/Board Member | 65 | 2019-09-08 |
Michael Roman
BRD | Director/Board Member | 66 | 2021-04-22 |
Paola Gonzalez
BRD | Director/Board Member | 54 | 2021-08-29 |
Holdings: Abbott Laboratories
| Name | Equities | % | Valuation |
|---|---|---|---|
ABBOTT INDIA LIMITED 74.99% | 15,934,048 | 74.99% | 4 355 M $ |
| 17,949,800 | 51.69% | 40 M $ | |
| 2,061,855 | 4.74% | 1 M $ |
Company details: Abbott Laboratories
Group companies: Abbott Laboratories
| Name | Category and Sector |
|---|---|
TwistDx Ltd.
 TwistDx Ltd. BiotechnologyHealth Technology Provides molecular testing and technology |
Biotechnology
|
St. Jude Medical International Holding SARL
 St. Jude Medical International Holding SARL Medical DistributorsDistribution Services Distributes medical devices |
Medical Distributors
|
St. Jude Medical Luxembourg SRL
 St. Jude Medical Luxembourg SRL Financial ConglomeratesFinance Functions as an investment holding company |
Financial Conglomerates
|
St. Jude Medical Luxembourg SRL
St. Jude Medical Luxembourg SRL Financial ConglomeratesFinance Functions as an investment holding company |
Financial Conglomerates
|
Abbott Laboratories GmbH
 Abbott Laboratories GmbH Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs |
Pharmaceuticals: Major
|
Other Medical Equipment, Supplies & Distribution
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.00% | -7.06% | -26.39% | -8.17% | 166B | |
| -1.66% | -2.57% | +3.57% | +6.12% | 110B | |
| -3.35% | -1.68% | +87.79% | +101.70% | 63.23B | |
| +1.51% | -0.03% | +13.33% | +92.89% | 62.71B | |
| -0.45% | -0.41% | -22.74% | -39.41% | 44.08B | |
| -2.07% | +2.74% | - | - | 38.1B | |
| -0.50% | -6.78% | -10.91% | -47.08% | 23.63B | |
| -0.69% | -1.69% | -0.02% | +17.93% | 21.57B | |
| +2.63% | +9.81% | -0.08% | -34.36% | 20.88B | |
| -0.59% | +1.68% | -19.68% | +12.35% | 20.28B | |
| Average | -0.10% | -0.65% | +2.76% | +11.33% | 57.07B | |
| Weighted average by Cap. | -0.03% | -2.34% | +1.37% | +16.22% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABT Stock
- Company Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
